Autolus Therapeutics (6A3A) Stock Price & Analysis
6A3A Stock Chart & Stats
- Day’s Range
- EUR 1.33 - EUR 1.37
- 52-Week Range
- EUR 1.04 - EUR 2.16
- Previous Close
- EUR 1.43
- Volume
- N/A
- Average Volume (3M)
- 60
- Market Cap
- EUR 362.24M
- Enterprise Value
- EUR 590.54M
- Total Cash (Recent Filing)
- EUR 201.63M
- Total Debt (Recent Filing)
- EUR 83.51M
- Price to Earnings (P/E)
- ―
- Beta
- 1.60
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Growth
Rapidly rising AUCATZYL revenue and higher full-year guidance indicate that Autolus is converting its lead therapy into meaningful commercial traction. Continued adoption can strengthen operating leverage, support reinvestment in the pipeline, and provide a more durable funding source than pre-commercial financing alone.
Gross Margin Improvement
The sharp margin inflection suggests manufacturing scale and cost-per-batch improvements are beginning to improve the economics of AUCATZYL. If the targeted mature margin is achieved, higher contribution per treatment could reduce cash burn and create a stronger foundation for sustained commercial profitability.
Expanding Commercial Footprint
A growing network of authorized treatment centers expands patient access and increases the practical capacity to deliver AUCATZYL. Broader coverage can support continued prescription growth, deepen the commercial infrastructure, and make revenue expansion less dependent on a small number of early sites.
Bears Say
Persistent Cash Burn
Large recurring operating and free-cash outflows show that the business remains dependent on external funding while commercialization and development continue. Unless revenue growth and margins improve materially, ongoing burn can consume liquidity, constrain investment choices, and prolong the path to self-funded operations.
Continued Operating Losses
Losses have narrowed but remain substantial, indicating that current product revenue does not yet cover the company’s commercial, research, and corporate cost base. Persistent deficits limit financial flexibility and make future earnings dependent on successful scaling, cost control, and execution across the pipeline.
Milestone-Contingent Financing
A material portion of expected financing is conditional on future commercial performance, so the projected runway is not entirely secured by current liquidity. Failure to meet revenue milestones could reduce available funding while development spending continues, increasing execution pressure and refinancing risk.
Autolus Therapeutics News
6A3A FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
What is Autolus Therapeutics’s market cap?
When is Autolus Therapeutics’s upcoming earnings report date?
How were Autolus Therapeutics’s earnings last quarter?
Is Autolus Therapeutics overvalued?
Does Autolus Therapeutics pay dividends?
What is Autolus Therapeutics’s EPS estimate?
How many shares outstanding does Autolus Therapeutics have?
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Autolus Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Autolus Therapeutics Stock Smart Score
Company Description
Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christian Martin Itin
- Employees
- 752
- Website
- www.autolus.com
- Address
- The MediaWorks, London, GL, W12 7FP, GB
Autolus Therapeutics (6A3A) Earnings & Revenues
6A3A Company Deck
6A3A Earnings Call
Earnings Call SentimentPositive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.
View all DE:6A3A earnings summaries6A3A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |
